Assessment of Relations between Clinical Outcome of Ischemic Stroke and Activity of Inflammatory Processes in the Acute Phase Based on Examination of Selected ParametersPalasik W.a · Fiszer U.a · Lechowicz W.b · Czartoryska B.c · Krzesiewicz M.a · Lugowska A.c
Departments of aNeurology and Epileptology, Center for Medical Postgraduate Education, and bNeuropathology and cGenetics, Institute of Psychiatry and Neurology, Warsaw, Poland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background and Purposes: Inflammatory factors play an important role in the pathogenesis of ischemic stroke. They may influence circulation during the acute phase of stroke and enhance the ischemic region. Materials and Methods: We examined 51 patients – 36 patients in the early stage of stroke, i.e. the first 24 h after onset. Of these, 15 patients had infection and 21 had no infection during the week preceding stroke. There were 15 patients with noninflammatory diseases in the control group. We analyzed parameters of inflammation such as: activity of serum chitotriosidase by fluorimetric assay, C-reactive proteins (CRP), number of white body cells (WBCs), IgG and fibrinogen. We also assessed the neurological stage according to the Scandinavian Stroke Scale (SSS). Results: In our study, we observed a statistically significant difference (p < 0.05) in the activity of most parameters of inflammation. This difference could be seen in the levels of CRP, number of WBCs and the activity of chitotriosidase, apart from IgG and fibrinogen, between the control group and groups with versus without infection. A significantly increased level of CRP (p < 0.0005) and fibrinogen (p > 0.01) was found on the first day in the stroke group as compared to the control group. The neurological stage on day 4 after stroke, assessed according to the SSS, was significantly worse in the group of patients with infection before stroke than in stroke patients without infection (p < 0.008). Conclusion: These results suggest the importance of active inflammatory processes in the pathogenesis of stroke. We observed increased activity of chitotioridase, a parameter of the inflammatory process, in stroke. This study is one more proof that inflammatory processes caused by infection may influence the occurrence of stroke and worsen its outcome. It could be another step towards understanding immunological processes during the acute phase of stroke. The study may also help establish new diagnostic and therapeutic strategies and could be a useful tool for prophylaxis.
© 2005 S. Karger AG, Basel
- Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000;31:2325–2329.
- Hollak CE, van Wealy S, van Oers MH, Aerts JM: Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288–1292.
Czartoryska B, Fiszer U, Ługowska A: Chitotriosidase activity in cerebrospinal fluid as a parameter of inflammatory processes in neurological diseases. J Lab Med 2001;25:77–81.
- Sandercock P, Molyneux A, Warlow C: Value of computed tomography in patients with stroke: Oxfordshire Community Stroke Project. Br Med J (Clin Res Ed) 1985;290:193–197.
Scandinavian Stroke Study Group: Multicenter trial of hemodilution in ischemic stroke: Background and study protocol. Stroke 1985;16:885–890.
Träxler G: Kinetische Nephelometrie. Medizintechnik 1979;99:79–84.
- Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifaji N: Analytical evaluation of particle-enhanced immunonephelometric assay for C-reactive protein, serum amyloid and mannose binding protein in human serum. Ann Clin Biochem 1998;35:745–753.
- Samuel MA: Inflammation and neurological disease. Curr Opin Neurol 2004;17:307–309.
- Unkila-Kallio L, Kallio MJ, Eskola J, Peltola H. Unkila-Kallio L, Kallio MJ, Eskola J, Peltola H: Serum C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in acute hematogenous osteomyelitis of children. Pediatrics 1994;93:59–62.
- Valmari P: White blood cell count, erythrocyte sedimentation rate and serum C-reactive protein in meningitis: Magnitude of the response related to bacterial species. Infection 1984;12:328–330.
- Clauss RH: Coagulation physiological rapid method for the determination of fibrinogen. Acta Haematol 1957;17:237–246.
- Di Napoli M, Papa F, Bocola V: Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 2001;32:133–138.
- Di Napoli M, Papa F, Bocola V: C-reactive protein in ischemic stroke: An independent prognostic factor. Stroke 2001;32:917–924.
- Sachse C, Henkel E: An evaluation of the CELL-DYN 1700 haematology analyser: Automated cell counting and three-part leukocyte differentiation. Clin Lab Haematol 1996;18:171–180.
Grau AJ: Infection, inflammation and cerebrovascular ischemia. Neurology 1997;49:S47–S51.
- Becker KJ: Inflammation and acute stroke. Curr Opin Neurol 1998;11:45–49.
- Bova IY, Bornstein NM, Korczyn AD: Acute infection as a risk factor for stroke. Stroke 1996;27:2204–2206.
- Macko RF, Ameriso SF, Barndt R, Clough W, Weiner JM, Fisher M: Precipitants of brain infarction. Roles of preceding infection/inflammation and recent psychological stress. Stroke 1996;27:1999–2004.
- Grau AJ, Buggle F, Becher H, Werle E, Hacke W: The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res 1996;82:245–255.
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
- Anuk T, Assayag EB, Rotstein R, Fusman R, Zeltser D, Berliner S, Avitzour D, Shapira I, Arber N, Bornstein NM: Prognostic implications of admission inflammatory profile in acute ischemic neurological events. Acta Neurol Scand 2002;106:196–199.
- Ford ES, Giles WH: Serum C-reactive protein and self-reported stroke: Findings from the Third National Health and Nutrition Examination Survey. Arterioscler Throm Vasc Biol 2000;20:1052–1056.
- Di Napoli M, Papa F: Villa Pini Stroke Data Bank Investigators: Inflammation, haemostatic parameters, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke. Stroke 2002;33:1763–1771.
- Akapov SE, Simonian NA, Grigorian GS: Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996;27:1739–1743.
- Tarnacka B, Gromadzka G, Członkowska A: Increased circulating immune complexes in acute stroke: The triggering role of Chlamydia pneumoniae and cytomegalovirus. Stroke 2002;33:936–940.
- Fiszer U, Korczak-Kowalska G, Palasik W, Korlak J, Górski A, Członkowska A: Increased expression of adhesion molecule CD18 (LFA-1beta) on the leukocytes of peripheral blood in patients with acute ischemic stroke. Acta Neurol Scand 1998;97:221–224.
- Audebert HJ, Pellkofer TS, Wimmer ML, Haberl RL: Progression in lacunar stroke is related to elevated acute phase parameters. Eur Neurol 2004;51:125–131.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.